Skip Navigation

Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06001788

Study #:
STUDY00160165

Start Date:
Apr 04, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06001788

View Complete Trial Details & Eligibility at ClinicalTrials.gov